Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Share-based Compensation (2016 - 2025)

Enanta Pharmaceuticals' Share-based Compensation history spans 14 years, with the latest figure at $3.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 32.76% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $16.7 million, down 31.41%, while the annual FY2025 figure was $18.6 million, 30.71% down from the prior year.
  • Share-based Compensation reached $3.8 million in Q4 2025 per ENTA's latest filing, down from $4.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $8.1 million in Q4 2023 to a low of $3.8 million in Q4 2025.
  • Average Share-based Compensation over 5 years is $6.0 million, with a median of $5.9 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: surged 38.87% in 2022, then crashed 47.73% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $6.1 million in 2021, then increased by 17.77% to $7.1 million in 2022, then increased by 13.45% to $8.1 million in 2023, then plummeted by 30.04% to $5.7 million in 2024, then crashed by 32.76% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Share-based Compensation are $3.8 million (Q4 2025), $4.0 million (Q3 2025), and $4.2 million (Q2 2025).